172 related articles for article (PubMed ID: 35039473)
1. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.
Begna KH; Kittur J; Gangat N; Alkhateeb H; Patnaik MS; Al-Kali A; Elliott MA; Hogan WJ; Litzow MR; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Blood Cancer J; 2022 Jan; 12(1):7. PubMed ID: 35039473
[TBL] [Abstract][Full Text] [Related]
2. [Outcomes of adult patients with
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
[No Abstract] [Full Text] [Related]
3. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
Jabbour E; Daver N; Champlin R; Mathisen M; Oran B; Ciurea S; Khouri I; Cornelison AM; Ghanem H; Cardenas-Turanzas M; Popat U; Ravandi F; Giralt S; Garcia-Manero G; Cortes J; Kantarjian H; de Lima M
Am J Hematol; 2014 Apr; 89(4):395-8. PubMed ID: 24375514
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience.
Yu Z; Yao Y; Zhang Y; Chen J; Xu Y; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Wu D; Wang Y
Hematology; 2023 Dec; 28(1):2212534. PubMed ID: 37191301
[TBL] [Abstract][Full Text] [Related]
5. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Tenold ME; Moskoff BN; Krishnan R; Rosenberg AS; Hoeg RT; Abedi M; Tuscano JM; Jonas BA
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007
[TBL] [Abstract][Full Text] [Related]
7. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
Wattad M; Weber D; Döhner K; Krauter J; Gaidzik VI; Paschka P; Heuser M; Thol F; Kindler T; Lübbert M; Salih HR; Kündgen A; Horst HA; Brossart P; Götze K; Nachbaur D; Köhne CH; Ringhoffer M; Wulf G; Held G; Salwender H; Benner A; Ganser A; Döhner H; Schlenk RF
Leukemia; 2017 Jun; 31(6):1306-1313. PubMed ID: 28138160
[TBL] [Abstract][Full Text] [Related]
8. Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
Mohty R; Massoud R; Chakhachiro Z; Mahfouz R; Nassif S; El-Cheikh J; Bazarbachi A; Abou Dalle I
Leuk Res; 2021 Jun; 105():106568. PubMed ID: 33857784
[TBL] [Abstract][Full Text] [Related]
9. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
Tavernier E; Le QH; Elhamri M; Thomas X
Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).
Schnetzke U; Fix P; Spies-Weisshart B; Schrenk K; Glaser A; Fricke HJ; La Rosée P; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1391-7. PubMed ID: 24728467
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Fong CY; Grigoriadis G; Hocking J; Coutsouvelis J; Muirhead J; Campbell P; Paul E; Walker P; Avery S; Patil S; Spencer A; Schwarer A; Wei A
Leuk Lymphoma; 2013 Feb; 54(2):336-41. PubMed ID: 22812445
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
13. [Treatment responses, outcomes, and prognostic factors associated with them in patients with secondary acute myeloid leukemia].
Ma L; Zhao T; Chen YY; Jiang H; Xu LP; Zhang XH; Wang Y; Sun YQ; Mo XD; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):124-131. PubMed ID: 36948866
[No Abstract] [Full Text] [Related]
14. Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.
Pfeiffer T; Schleuning M; Mayer J; Haude KH; Tischer J; Buchholz S; Bunjes D; Bug G; Holler E; Meyer RG; Greinix H; Scheid C; Christopeit M; Schnittger S; Braess J; Schlimok G; Spiekermann K; Ganser A; Kolb HJ; Schmid C
Haematologica; 2013 Apr; 98(4):518-25. PubMed ID: 22983588
[TBL] [Abstract][Full Text] [Related]
15. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
Ye P; Pei R; Jin J; Sun J; Li K; Cao J; Zhou D; Lu Y
Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
[TBL] [Abstract][Full Text] [Related]
16. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
17. Mayo Clinic experience with 1123 adults with acute myeloid leukemia.
Begna KH; Ali W; Naseema Gangat ; Elliott MA; Al-Kali A; Litzow MR; Christopher Hook C; Wolanskyj-Spinner AP; Hogan WJ; Patnaik MM; Pardanani A; Zblewski DL; Chen D; He R; Viswanatha D; Hanson CA; Ketterling RP; Tefferi A
Blood Cancer J; 2021 Mar; 11(3):46. PubMed ID: 33654065
[TBL] [Abstract][Full Text] [Related]
18. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL
Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
20. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
Ahmed T; Holwerda S; Klepin HD; Isom S; Ellis LR; Lyerly S; Manuel M; Dralle S; Berenzon D; Powell BL; Pardee TS
Leuk Res; 2015 Sep; 39(9):945-9. PubMed ID: 26154683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
